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1. Introduction  
Pomegranate (Punica granatum L.) is considered one of the oldest known edible fruits and is 
the symbolic of abundance and prosperity. For thousand of years, many cultures have 
believed that pomegranate have beneficiary effects on health, fertility, longevity and rebirth. 
The recent interest for this fruit is not only because of the pleasant taste, but also due to the 
scientific evidences that suggest therapeutic activity such as anti-atherogenic, antiparasitic, 
antimicrobial, antioxidant, anticarcinogenic and antiinflammatory effects. These beneficial 
effects were attributed to the antioxidative properties of pomegranate phenolic compounds, 
tannins and anthocyanins as well as other phytochemicals. The constituents of pomegranate 
have been thoroughly investigated, however, clinical trials are in progress to explore the 
therapeutic potential of pomegranate products, particularly determining preventive efficacy 
of pomegranate extracts in cancer, cardiovascular diseases, inflammation, diabetes and 
ultraviolet radiation-induced skin damage. In order to facilitate the further investigations 
the information contained in this work is based upon the immense work on impact of 
administration of pomegranate extracts, particularly in cancer prevention such as skin, 
prostate, breast, and colon.  
2. The constituents of pomegranate and derived products  
Along with olives, figs and grapes, pomegranates are among the first plants to have been 
cultivated by man. Pomegranate (Punica granatum L.) is considered one of the oldest known 
edible fruit that is mentioned in the Koran, the Bible, the Jewish Torah, and the Babylonian 
Talmud as ‘Food of Gods’ that is symbolic of plentyness, fertility and prosperity 
(Madihassan, 1984; Aviram et al., 2000; Seeram et al., 2006). The pomegranate, a mystical 
and highly distinctive fruit, is the predominant member of two species comprising the 
Punicaceae family. The genus name Punica, was the Roman name for Carthage, where the 
best pomegranates were known to grow. Pomegranate is known by the French as grenade, 
the Spanish as granada (derived from the ancient city of Granada), and literally translates to 
seeded ("granatus") apple ("ponium") (Jurenka, 2008).  
In ancient Greek mythology, the edible part of pomegranate known as the “fruit of the 
dead”, containing considerable amounts of saccharides, polyphenol, and available in Hades 
for its residents. Hades benefitted amorously when six pomegranate seeds from his 
kingdom sealed for him the betrothal of the daughter of Zeus and Demeter. The 
www.intechopen.com
 
Cancer Prevention – From Mechanisms to Translational Benefits 
 
332 
Babylonians regarded the seeds as an agent of resurrection, the Persians as conferring 
invincibility on the battle field and for ancient Chinese alchemical adepts; the bright red 
juice was mythopoetically regarded as a “soul concentrate”, a synonym to human blood, 
conferring to longevity and immortality (Dahham et al., 2010). Since ancient times, the 
pomegranate has been used extensively in the folk medicine of many cultures as a “healing 
food” in order to eliminate parasites, as an antihelmintic and vermifuge, antipyretic, and to 
treat and cure aphtae, ulcers, diarrhea, acidosis, dysentery, hemorrhage, microbial 
infections, and respiratory pathologies. It also features prominently in the ceremonies, art, 
and mythology of the Egyptians and Greeks, and was the personal emblem of Maximilian, 
the Holy Roman Emperor (Longtin, 2003; Larrosa et al., 2010; Lee et al., 2010). 
The pomegranate fruit is round, with leathery skin or rind, typically yellow, overlaid with 
light or deep pink or rich red. The edible part of the fruit, the arils can be preserved as syrup or 
used for juice, jam, jelly, wine, vinegar, and fruit leather production, and can be an alternative 
to flavoring and coloring used in beverages (Maestre et al., 2000; Fadavi et al., 2005; Ozgen et 
al., 2008; Al-Said et al., 2009; Mousavinejad et al., 2009; Akbarpour et al., 2010).  
2.1 Chemical composition of pomegranates 
The pomegranate tree can be divided into several anatomical compartments: seed, juice, 
peel, leaf, flower and root bark, each of which is widely used in therapeutic and food 
formulas, and cosmetics due in large part to the scientifically supported health benefits on 
arteriosclerosis, cholesterol levels and cancer prevention.The other parts are good source of 
tannins, dyes, and alkaloids (Khan, 2009; Viuda-Martos et al., 2010; Wang et al., 2010). The 
chemical composition of the pomegranate and its products depends on the cultivar, growing 
region, and climate, the fruit’s stage of maturity, cultural practices and manufacturing 
systems (Badenes et al., 1998; Dumas et al., 2003; Toor et al., 2006; Raffo et al., 2006, 
Borochov-Neori et al., 2009; Zarei et al., 2011). Tables 1 & 2 show the chemical composition 
of pomegranate fruit and phytochemicals in pomegranate and its parts.  
 
Constituent  
Moisture 72.6-86.4% 
Protein 0.05-1.6% 
Fat 0.01-0.9% 
Mineral elements 0.36-0.73% 
Fibre 3.4-5.0% 
Carbohydrates 15.4-19.6% 
Calcium 3.0-12.0 mg 
Phosphorus 8.0-37.0 mg 
Iron 0.3-1.2 mg 
Sodium 3.0 mg 
Magnesium 9.0 mg 
Ascorbic acid (Vitamin C) 4.0-14.0 mg 
Thiamine (Vitamin B1) 0.01 mg 
Riboflavine (Vitamin B2) 0.012-0.03 mg 
Niacine 0.18-0.3 mg 
*Values per 100 g of edible portions  
Table 1. Chemical Composition of Pomegranate* (Yilmaz, 2007). 
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Plant Component   Constituents 
  
Pomegranate juice Anthocyanins; glucose; ascorbic acid; phenolics such as 
ellagic acid, gallic acid, caffeic acid, catechin, 
epigallocatechin gallate (EGCG), quercetin, rutin; 
mineral elements; aminoacids 
Pomegranate seed oil  Punicic acid; ellagic acid; fatty acids; sterols 
Pomegranate pericarp (peel, 
rind)  
Phenolic compounds like punicalagins, gallic acid, 
catechin, EGCG, quercetin, rutin, anthocyanidins, other 
flavonoids 
Pomegranate leaves  Ellagitannins (punicalin and punicafolin); flavonols such 
as luteolin and apgenin 
Pomegranate flower  Gallic acid, triterpenoids such as ursolic,maslinic and 
asiatic acid 
Pomegranate roots and bark  Ellagitannins; piperidine alkaloids 
Table 2. Phytochemicals of Pomegranate (Jurenka, 2008). 
About 50% of the total fruit weight corresponds to the peel, which is an important source of 
bioactive compounds such as phenolics, flavonoids, ellagitannins (ETs), and 
proanthocyanidin compounds (Li et al., 2006), minerals (Mirdehghan & Rahemi, 2007), and 
complex polysaccharides (Jahfar et al., 2003). Significant variations in organic acids, phenolic 
compounds, sugars, water-soluble vitamins, and minerals of pomegranates have been 
reported by various researchers (Davidson et al., 2009; Tezcan et al., 2009).  
The edible part of the pomegranate fruit consists of 40% arils and 10% seeds. The arils are 
comprised of approximately 80% juice and 20% seed. The juice of arils contain 85% water, 
10% total sugars (glucose, sucrose, and fructose) (Melgarejo & Artes, 2000), and 1.5% pectin, 
organic acids (citric, malic, tartaric, succinic, fumaric, ascorbic acid) (Tezcan et al., 2009), 
fatty acids (i.e. conjugated linoleic acid, linoleic acid, punicic acid and eleostearic acid) 
(Fadavi et al., 2006) and amino acids (i.e. proline, valin, and methionine) (Seppi & Franciosi, 
1980), and bioactive compounds (phenolics and flavonoids) (Dahham et al., 2010). 
Pomegranate fruit is a rich source of two types of polyphenolic compounds: anthocyanins 
and hydrolyzable tannins, which account for 92% of the antioxidant activity of the whole 
fruit (Gil et al., 2000). The soluble polyphenol content in pomegranate juice varies between 
0.2 and 1.0% depending on variety (Narr Ben et al., 1996). The seeds are a rich source of 
lipids; of which comprised to 12% to 20% of total seed weight and characterized by a high 
content of polyunsaturated (n-3) fatty acids such as linolenic, linoleic, and other lipids such 
as punicic acid, oleic acid, stearic acid, and palmitic acid (Ozgul-Yucel, 2005). The seeds also 
contain protein, crude fibers, vitamins, minerals, pectin, sugars, polyphenols, isoflavones 
(mainly genistein), the phytoestrogen coumestrol, and the sex steroid, estrone (Singh et al., 
1990; Singh & Sethi, 2003; El-Nemr et al., 2006; Syed et al., 2007). 
Pomegranate flowers (gulnar) contain a variety of secondary metabolites: i) polyphenols, 
including gallic acid (Huang et al., 2005b), ellagic acid and ethyl brevifolin-carboxylate 
(Wang et al., 2006), and ii) triterpene acids consisting of oleanolic, ursolic (Huang et al., 
2005a), maslinic and asiatic (Batta & Rangaswami, 1973). In folk medicine the decoction of 
flowers is used to stop bleeding and purging (Sivarajan & Balachandran, 1994; Jafri et al., 
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2000). The polyphenols in pomegranate flowers have strong antioxidant activity (Oswa et 
al., 1987); ellagic acid had a marked inhibitory effect on the occurrence and development of 
tumours in mice (Boukharta et al., 1992), triterpenes show antimutagenic and 
anticarcinogenic effects (Ovesná et al., 2004); and oleanolic acid significantly enhanced acute 
glucose-stimulated insulin secretion at basal and stimulatory glucose concentrations in 
pancreatic b-cell , and such effects may contribute to the antidiabetic properties (Teodoro et 
al., 2008).  
Pomegranate fruit extracts/constituents possesses immense biological activities such as 
anticarcinogenic (Whitley et al., 2003; Afaq et al., 2005), antibacterial (Akiyama et al., 2001; 
Prashanth et al., 2001; Duman et al., 2009), antidiarrhoeal (Das et al., 1999), antifungal (Dutta 
et al., 1998), antiulcer (Gharzouli et al., 1999), antioxidant activity and free radical 
scavenging capability (Schubert et al., 1999; Aviram et al., 2000; Festa et al., 2001), 
strengthening of the immune system (Lee et al., 2008), prevention of heart disease 
(Johanningsmeier & Harris, 2011) and liver fibrosis (Thresiamma & Kuttan, 1996), and 
inhibition of lipid peroxidation even at lower concentrations than vitamin E (Rosenblat et 
al., 2003). All these therapeutical activities are related to the presence of diverse ‘phenolic 
compounds’, including gallic acid, protocatechinunic acid, chlorogenic acid, caffeic acid, 
ferulic acid, coumaric acid, and catechin and hydrolysable tannins (such as punicalin, 
pedunculagin, punicalagin, corilagin, casuarinin, punicacortein, granatin and ellagic acid), 
and anthocyanins (delphinidin, cyanidin and pelargonidin 3-glucosides and 3,5-
diglucosides) (Amakura et al., 2000; Noda et al., 2002; Poyrazoglu et al., 2002; Kulkarni & 
Aradya, 2005; Viuda-Martos et al., 2010).  
The bright colour of pomegranate flowers and arils is due to anthocyanins (Afaq et al., 
2005); however, only one anthocyanin compound (i.e. pelargonidin-3,5-diglucoside) has yet 
been identified in pomegranate flowers using HPLC (Miguel et al., 2009), whereas in 
pomegranate juice, principally cyanidin-3-O-glucoside, cyanidin-3,5-di-O-glucoside, 
delphinidin-3-O-glucoside, delphinidin-3,5-di-Oglucoside, pelargonidin-3-O-glucoside, and 
pelargonidin-3,5-di- O-glucoside, have been reported (Lansky & Newman 2007; Jaiswal et 
al., 2010). 
Tannins, high-molecular-weight plant polyphenols, are divided into 3 chemically and 
biologically distinct groups: condensed tannins or proanthocyanidins, hydrolyzable tannins 
or elagitannins (ETs), and gallotannins (GTs) (Seeram et al., 2005). Pomegranate leaves 
contain unique tannins such as punicalin and punicafolin, and also have glycosides of 
apigenin, a flavone with progestinic (Zand et al., 2000) and anxiolytic (Paladini et al., 1999) 
properties. Pomegranate peel are rich in hydrolyzable tannins, mainly punicalin, 
pedunculagin, and punicalagin (Seeram et al., 2006), which differ from proanthocyanidins in 
their chemical structures. In addition to ETs, pomegranate peel contains hydroxybenzoic 
acids such as gallagic, ergot alkaloid (EA), and EA glycosides (Amakura et al., 2000); 
anthocyanidins are principally cyanidin, pelargonidin, and delphinidin (Noda et al., 2002) 
and flavonoids such as kaempferol, luteolin, and quercetin (Van Elswijk et al., 2004). 
Al-Maiman & Ahmad (2002) showed the amounts of potassium, calcium and sodium were 
highest in both juice and seeds followed by magnesium, phosphorous, zinc, iron and 
copper. The authors stated that pomegranate can be a good source of nutrients and variation 
could originate from the pomegranate cultivar, and agro-climatic. Akpinar-Bayizit (2010) 
reported that although processing steps include clarification and filtration, the pomegranate 
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juices in Turkish market were a good source for minerals such as potassium (1283.30 mg/L), 
calcium (107.53 mg/L), sodium (96.02 mg/L), phosphorus (76.54 mg/L) and magnesium 
(67.22 mg/L). The high mineral content of pomegranate juices could contribute to the daily 
intake of these constituents in the human diet. 
2.2 Pomegranate fruit derived products  
Pomegranate can be consumed as fresh, fruit juice, fermented fruit juice, dried aril, frozen 
aril, minimally-processed aril, canned aril, jam, jelly, wine, vinegar, paste, fruit leather and 
in flavoring products. 
Pomegranate arils can either be consumed fresh or procesed (dried, frozen, canned and 
minimally-processed). The conventional utilization of wild pomegranate fruit lies in the 
drying seeds along with pulp (arils), which constitute a traditional product called as 
‘Anardana’ (Pruthi & Saxena, 1984). The dehydrated arils are acidic (7.8–15.4%), help in 
improving mouth-feel and digestion, and are widely used as acidulent in culinary 
preparations. The dried anardana contains acid (5.8-15.4%), total sugars (9.3-17.5%) and 
crude fiber as compared to fresh fruit. To obtain frozen arils the arils are put into 
polyethylene bags either with syrup of 15° Brix or coated with solid sugar and frozen in a 
chest freezer. For canned arils, used generally as an appartiser, the arils were put into metal 
tins with syrup of 15° Brix and sterilised for 10 minutes. In the production of minimally-
processed pomegranate aril pomegranates are chilled to 0°C, selected, washed and dried 
with a current of air at room temperature. They are conditioned in polyethylene bags that 
were heat-sealed and conserved in a chamber at 0°C for 10-15 days. These arils are used as a 
garnish for desserts and salad (Al-Maiman & Ahmad, 2002).  
Pomegranate juice can be extracted by using a spiral-type screw press without crushing the 
seeds. The juice is clarified by heating in a flash pasteurizer at 79-82°C cooling, settled for 24 
hours and filtered. The clear juice can be preserved by heat treatment or by using chemicals. 
The use of sulphur dioxide is banned for pomegranate due to loss of colour by bleaching 
action of SO2. Pomegranate juice represents one of the foods recently promoted for its health 
benefits since a glass of pomegranate juice contains about 40% of the Recommended Daily 
Allowance (RDA) of Vitamin C (Singh & Singh, 2004).  
Pomegrenate syrup of 60° Brix with an added acidity of 1.5% as citric acid has a bright 
purplish-red colour and a delightful taste and flavour. It was preserved by pasteurization. 
Preparation of jelly on a small-scale from sweet-sour pomegranates is described by Adsule 
et al. (1992) and Singh & Singh (2004). When making the jellies, approximately 50% of the 
total anthocyanins present in the juice of are lost. During storage at 5°C, certain colour 
differences were observed, which indicates that the pH was not the only parameter 
responsible for this characteristic.  
For preparation of wine, the whole furits are pressed without crushing or juice may be 
extracted from pomegranate grains, which gives a yield of 76 to 85% (Adsule & Patil, 1995). 
Sugar is added to the juice to obtain 22-23° Brix. The juice is fermented as in the same 
manner of red grape wine. The wine is flash pasteurized at 60°C and bottled hot (Singh & 
Singh, 2004).  
Pomegranate seed is a residue obtained from pomegranate juice production, ranging 
between 40 and 100 g/kg of fruit weight (Fadavi et al., 2006; Lansky & Newman, 2007). The 
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seeds are rich source of lipids, and the fatty acid component of pomegranate seed oil 
comprises over 95% of the oil, of which 99% is triacylglycerols. Minor components of the oil 
include vitamin E, sterols, steroids, and a key component of mammalian myelin sheaths, 
cerebroside (Tsuyuki et al., 1981).  
‘Pekmez’, a concentrated and shelf-life extended Turkish product, is generally produced 
from fruits containing high amounts of sugar such as grape, mulberry, carnob, apple, 
pomegranate, plum and apricot (Alparslan & Hayta, 2002; Demirozu et al., 2002). The first 
steps in pomegranate pekmez production is washing, granulating and crushing of the 
pomegranates. The pomegranate juice, obtained by pressing the crushed pomegranates by a 
pneumatical or mechanical press, is boiled with a calcareous substance called ‘pekmez earth’, 
white soil containing 70.40% CaCO3 or technical CaCO3, for deacidification and 
neutralization. The juice is clarified and concentrated usually in open vessels, and rarely 
under vacuum at 565 mm Hg and 66°C, up to 65–68° Brix; this product is called ‘liquid 
pekmez’. The liquid pekmez can be consumed either as liquid or solidified at 6oC for 2-3 days 
via addition of hydrocolloids, to produce ‘solid pekmez’, which has a pasty form that is easily 
spread on a slice of bread. 
The ‘pomegranate leather (pestil)’ is another Turkish pomegranate derived product that can be 
stored for a long time without deterioration. Pomegranates are washed, granulated, 
crushed, pressed and filtered to separate the seeds and skin. Pekmez earth is added to 
neutralize and clarify the fresh pomegranate juice. Clarified juice is filtered and is mixed 
with the wheat starch. Nuts such as walnut or hazelnut can be added in small pieces if 
desired. The juice and starch mixture is concentrated upto 40° Brix by boiling and 
continuous stirring. The puree is spread on cloths of 0.5–2.00 mm thickness and sun-dried 
until a mild, tasty, light and chewable leathery product is obtained. The dried pestil is 
folded, cut and stored in dry conditions (Maskan et al., 2002).  
The ‘pomegranate molasses (sour pomegranate pekmez, nar eksisi, pomegranate sauce)’, a 
traditional seasoning commonly used in salads and many dishes to improve the taste and 
aroma characteristics in Turkey, is a concentrated product produced simply by boiling, 
without the addition of further sugar or other additives (Poyrazoglu et al., 2002; Incedayi et 
al., 2010). Pomegranate molasses is a highly nutritive product since it is more concentrate 
and the have a high mineral content. Traditional methods are still being used to produce 
pomegranate molasses, of which requires cleaning, crushing, extraction, filtration, and 
evaporation (upto 35-65° Brix) in an open vessel or under vacuum. Clarification is not 
recommended in pomegranate molasses since customers prefer bitterness and sourness that 
comes from phenolic substances and acidity (Vardin & Abbasoglu, 2004; Kaya & Sozer, 
2005). 
3. The biochemistry and pharmokinetics of pomegranate  
There is little knowledge about the absorption, bioavailability, biodistribution, and 
metabolism of the bioactive compounds present in pomegranate and in other fruits, 
although they probably have a similar pathway (Petti & Scully, 2009). The bioavailability of 
polyphenols varies according to the structure, glycosylation and solubility of the molecules 
which defined their extractability (Lecerf, 2006; Ozcan et al., 2011). In view of limited human 
studies, it appears that the bioavailability determinations of pomegranate polyphenols is 
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affected by individual variability, differential processing of pomegranate juice, and the 
analytical techniques used, which need to be sensitive enough to detect low postprandial 
concentrations of these metabolites (Basu & Penugonda, 2009). An in vitro study of 
pomegranate juice showed that phenolic compounds are available during the digestion in a 
quite high amount (29%), however, due to pH, anthocyanins are in large transformed into 
non-red forms and/or degraded and similar results are obtained for vitamin C (Pérez-
Vicente et al., 2002).  
The recent interest in pomegranate products is due to the fruit’s beneficial role in the 
prevention of prostate cancer, the prevention of the oxidation of both low density 
lipoprotein (LDL), high density lipoprotein (HDL), and cholesterol, reductions in blood 
pressure, arthritis, anemia, diarrhea, inflammation, gynecological diseases, atherosclerosis 
development, the stimulation of T-cell functions and production of cytokines, Alzheimer’s 
disease, and improvoment of sperm quality (Figure 1). These beneficial effects were 
attributed to the wide range of phytochemicals found in pomegranate. These 
phytochemicals are predominantly phenolic compounds as well as to those of sugar-
containing polyphenolic tannins and anthocyanins, including primarily hydrolysable 
ellagitannins, anthocyanins and other polyphenols. Gil et al. (2000) have demonstrated that 
one of the ellagitannins, punicalagins, is responsible for over 50% of the antioxidant activity 
of the pomegranate juice. The same reserachers indicated that as being water-soluble, 
commercial pomegranate juice obtained by pressing the fruit contain significant amounts of 
punicalagins, depending on the cultivar. Seeram et al. (2005) proposed punicalagin as a 
proper chemical marker for the authentication, quality control and standardization of 
pomegranate products. 
 
Fig. 1. Bioactive effects of pomegranate constituents. 
4. The health benefits of pomegranate derived products  
In recent years, the focus is on understanding the mechanisms of nutraceutic and health 
promoting potentials of the foods nutrients. Cancer, in terms of morbidity and mortality, is a 
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major health issue, eventhough there are advances in early detection and in treatment 
options. Cancer is an aggressive disease, which if not detected at an early stage can 
metastasize to other organs of the body. Carcinogenesis (cancer development) is a multistage 
process, influenced by mainly age, dietary habits and hormonal balance. There are three 
stages of cancer: initiation, promotion and progression (Surh, 2003). The hypothesis of 
alternative methods to prevent cancer seems to be practical and promising strategy to 
reduce cancer incidinces since treatment options for metastasized cancers remain 
inadequate. Chemoprevention focuses on cancer prevention by the administration of one or 
more synthetic or naturally occurring agents to suppress reverse or prolong the process of 
carcinogenesis (Mukhtar & Ahmad, 1999).  
It is clear that bioactive compounds present in daily diet, mainly in fruits and vegetables, 
have prevention potential in cancer by inhibiting carcinogenesis through cell-defensive and 
cell-death mechanism regulation. These chemopreventive effects may be attributed to a 
complex effect of various phenolic substances of antioxidant capacity (Khan et al., 2008).  
Pomegranate is rich in anthocyanins, 3-glucosides, 3,5-diglucosides of delphinidin, cyanidin 
and pelargonidin, ellagitannins and other phenolic compounds, which are known bioactive 
compounds with antioxidant and antitumoral activity (Ozgen et al., 2008; Chaturvedula et 
al., 2011; Zhang et al., 2011). Major hydrolysable tannins in pomegranates are gallotannins, 
ellagic acid tannins and gallagyl tannins, generally termed as punicalagins, and they have 
been shown to inhibit the proliferation of human cancer cells and modulate inflammatory 
subcellular signaling pathways due to a high antioxidant activity (Seeram et al., 2005).  
There are several studies conducted to evaluate the efficacy of pomegranate and its products 
as an anti-proliferative, anti-invasive, and pro-apoptotic agent in various cancer cell lines 
such as skin, prostate, breast, column, and blood cancer. Adams et al. (2006) revealed that 
pomegranate juice suppresses cancer activity through the combined antioxidant and anti-
inflammatory effects by modulating inflammatory cell signaling in colon cancer cells. Malik 
et al. (2005) suggested that pomegranate juice may have cancer chemopreventive as well as 
cancer-chemotherapeutic effects against prostate cancer in humans. Pomegranate fruit 
extract possesses remarkable antitumor-promoting effects in mouse skin.  
Researchers found that daily consumption of pomegranate juice may improve stress-
induced myocardial ischemia in patients who have coronary heart disease (CHD) and the 
pomegranate juice not only prevented hardening of the arteries by reducing blood vessel 
damage, but also reversed the progression of CHD (Sumner et al., 2005). Hartman et al. 
(2006) reported that pomegranate juice had beneficial effect on animal model of Alzheimer's 
disease since polyphenols are responsible for neural protection. 
4.1 Antioxidant activity  
Over the past few years, consumer demand-based research on functional foods gave a basis 
for traditional using of pomegranate, which lead to an increase in number of scientific 
papers concerning pomegranate and its products with health-improving effects (Mehta & 
Lansky, 2004; Rettig et al., 2008; Turk et al., 2008; Alam et al., 2010; Dai et al., 2010; Jadeja et 
al., 2010; Park et al., 2010). The reports have focused on in vitro, ex vivo, and in vivo 
antioxidant actions, of pomegranate and its products, which are attributed to the chemical 
composition. However, many other cellular processes are likely to be involved along with 
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bioactive compounds to enhance reactive oxygen species (ROS) elimination and inhibit ROS 
generation. Oxidative stress, refers to a cell state characterized by excessive production of 
ROS, has been given growing attention, as the generation of ROS, thus improved oxidative 
stress, can induce DNA damage and trigger redox-dependent transcription factors which 
lead to cancer, inflammatory, cardiovascular and neurodegenerative diseases, and aging 
(Evans et al., 2004; Franco et al., 2008; Ziech et al., 2010; Sedelnikova et al., 2010; Kryston et 
al., 2011; Martin et al., 2011). Nishikawa (2008) mentioned that sublethal levels of ROS can 
induce additional changes in DNA of tumor cells to make those cells malignant, stimulate 
the proliferation of cancer cells, and activate the expression of various molecules, some of 
which assist cancer cells to form metastatic colonies. 
The effect of pomegranate cultivars on antioxidant activity was target of study by some 
authors (Borochov-Neori et al., 2009; Mousavinejad et al., 2009; Pande & Akoh, 2009; 
Sadeghi et al. 2009). All authors reported considerable variation in some of the chemical 
composition profile (lipids, phenols, organic acids, vitamins, sugars) and antioxidant 
properties of pomegranate samples, independent on the antioxidant method performed. 
The antioxidant activity of pomegranate and its products was almost determined via in 
vitro trials and several methods could be used for its determination, however, 
pomegranate showed an antioxidant activity, independent on the antioxidant test assayed 
and generally with significant linear correlation between phenolic content and antioxidant 
capacity (Elfalleh et al., 2009). Seeram et al. (2005) stated that the antioxidant level in 
pomegranate juice was higher than found in other fruit juices, such as blueberry, 
cranberry, and orange. Schubert et al. (1999) and Gil et al. (2000) demonstrated that 
pomegranate juice and seed extracts have 2-3 times the in vitro antioxidant capacity of 
either red wine or green tea.  
Rosenblat et al. (2006) have shown that pomegranate extracts scavenge free radicals, and 
decrease macrophage oxidative stress and lipid peroxidation in animals. Studies in rats and 
mice confirmed the antioxidant properties of a pomegranate by-product extract made from 
whole fruit minus the juice, showing a 19% reduction in oxidative stress in mouse peritoneal 
macrophages (MPMs), a 42% decrease in cellular lipid peroxide content, and a 53% increase 
in reduced glutathione levels. A study in rats with chemically induced liver damage 
demonstrated that pretreatment with a methanolic extract of pomegranate peel enhanced or 
maintained the free-radical scavenging activity of the hepatic enzymes such as catalase, 
peroxidase, and superoxide dismutase to values comparable with control values, whereas 
resulted in 54% reduction of lipid peroxidation values compared to controls (Chidambara 
Murthy et al., 2002). 
Using the FRAP (ferric reducing/antioxidant power) assay, Guo et al. (2008) found that 
consumption of 250 mL pomegranate pulp juice daily for four weeks by healthy elderly 
subjects resulted in increased plasma antioxidant capacity, while subjects consuming apple 
juice experienced no significant increase. In addition, subjects consuming the pomegranate 
pulp juice exhibited significantly decreased plasma carbonyl content, a biomarker for 
oxidant/antioxidant barrier impairment in various inflammatory diseases.  
Several works have demonstrated that peel, seeds, arils have antioxidant activity, 
nevertheless, after ingestion those antioxidant compounds, mainly tannin components, are 
metabolized by gut bacteria into urolithins, which readily enter systemic circulation. 
Bialonska et al. (2009a) studied the antioxidant activities of seven urolithins derivatives in a 
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cell-based assay in order to reflect bioavailability of the test compound to the cells, and the 
antioxidant activity is evaluated in the cellular environment and in terms of inhibition of 
intracellular generation of reactive oxygen species. They found that urolithins exhibited a 
significant antioxidant activity correlated with the number of hydroxyl groups as well as 
lipophilicity of the molecules. 
4.2 Anticarcinogenic/antitumoral activity  
The critical success factor in cancer chemoprevention is the capacity of the agent to 
selectively inhibit proliferation and/or induce apoptosis in malignant cells, preserving 
normal cells. Pomegranate, consumed as whole fruit, juice, or any form of derivates, possess 
anti-proliferative, pro-apoptotic, and/or anti-angiogenic effects superior to those observed 
with their isolated active compounds, suggesting therapeutic strategies that may depart 
from preference for pure single agents. There are several publications on the 
anticarcinogenic effects of pomegranate (Ahmed et al., 2005; Jeune et al., 2005; Malik et al., 
2005; Syed et al., 2007; Lansky & Newman, 2007; Hajimahmoodi et al., 2008; Jurenka, 2008, 
Sartippour et al. 2008; Adams et al., 2010; Adhami et al., 2010; Faria & Calhau, 2010,2011; 
Miguel et al., 2010). Therefore, due to the vast explosion of interest in pomegranate as a 
functional food and therapeutic source the present work is launched to make a review that 
highlights anticarcinogenic activity of pomegranate and its products of recently published 
works. 
4.2.1 Prevention of skin cancer  
There is an urgent need to develop mechanism-based approaches for the 
prevention/therapy of lethal skin cancer (non-melanoma). Skin is the organ most accessible 
to sunlight, and directly suffers from the deleterious effects of ultraviolet (UV)1 radiation, 
that is known to accelerate aging changes, causing fine and coarse wrinkling, rough skin 
texture, dryness, telangiectasia and dyspigmentation, resulting in skin cell DNA damage 
(Afaq, 2011). The increase in incidinces of skin cancer due to constant exposure of skin to 
environmental carcinogens, such as chemical agents and ultraviolet radiation, provides a 
strong basis for chemoprevention (Gupta & Mukhtar, 2002). There is a considerable 
attention on the use of naturally occurring botanicals for their potential preventive effect 
against UV-mediated damages referred to as photochemopreventive effects (Afaq et al., 2005). 
In general, skin carcinogenesis, being a stepwise process of all three distinct stages, is an 
effective model for cancer chemoprevention (Richmond & Viner, 2003).  
Hora et al. (2003) investigated pomegranate seed oil (PSO) stated that PSO appears to be a 
natural product with potential as a topical chemopreventive agent against skin cancer, 
through inhibition of PG biosynthesis and ornithine decarboxylase. PSO treatment did not 
delay the appearance of tumors, but significantly decreased the rate of tumor development, 
skin tumor multiplicity, and ornithine decarboxylase activity during 20 weeks of promotion. 
They stated that PSO, being rich in punicic acid, has inhibitory effect on PG biosynthesis, as 
well as inhibiting upstream eicosanoid enzyme, phospholipase A2.  
Murthy et al. (2004) studied the wound healing activity of phenol-rich methanolic extract of 
dried pomegranate peel on the skin of Wistar rats. Following the application of the extract, 
formulated as a water-soluble gel, the animals treated with 5% gel showed complete healing 
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after 10 days, whereas in rats treated with 2.5% gel, healing was observed on day 12, in 
contrast to the positive control animals receiving the blank gel, which took 16–18 days for 
complete healing. The animals treated with 2.5% gel showed moderate healing (55.8% and 
40.8% healing compared with negative and positive controls, respectively), whereas the 
group treated with 5.0% gel showed good healing (59.5% and 44.5% healing compared with 
negative and positive controls, respectively). Histopathological studies supported the 
wound healing increased on application of the gels.  
Afaq et al. (2005) showed that pretreatment of mouse skin with pomegranate fruit extract 
modulated the activation of mitogen-activated protein kinase (MAPKs) and nuclear factor 
kappa B (NF-κB), in the 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced or ultra 
violet-B induced skin carcinogenesis model. Aslam et al. (2006) assessed the cosmeceutical 
value of pomegranate where aqueous fraction of the peel was shown to stimulate type I 
procollagen synthesis and inhibit MMP-1 production by human dermal fibroblasts. Syed 
et al. (2006) reported the remarkable photochemopreventive effects of pomegranate fruit 
extract (PFE) against UVA using normal human epidermal keratinocytes (NHEK) as a test 
system. PFE, extracted edible part of fruit with acetone, treatment was shown to inhibit 
UVA-induced phosphorylation of STAT3, ERK1/2 and AKT1 in human epidermal cells. 
In addition, the inhibitory effect of PFE on UVA-mediated phosphorylation of mTOR and 
p70S6K may have a regulatory effect on the rate of protein synthesis and activation of 
tumor cell proliferation. 
In a study pretreatment of EpiDerm with pomegranate juice, oil or by-product resulted in 
marked inhibition in the number of cyclobutane primidine dimers (CPDs) and 8-hydroxy-2-
deoxyguanosine (8-OHdG) positive cells, ultimately, showing a protective effect of against 
UVB-mediated DNA damage. UVB irradiation results in the induction in metalloproteinases 
(MMPs) which degrade extracellular matrix proteins, and eventually, cause skin wrinkling. 
It was shown that all three components of pomegranate were able to inhibit UVB-induced 
expressions of MMPs as well as MMP-2 and MMP-9 activity in the EpiDerm (Zaid et al., 
2007). Cell culture and animal studies have also supported that intake of pomegranate is 
associated with decreased skin cancer risk (Pacheco-Palencia et al., 2008). Afaq et al. (2009) 
found that pretreatment of human reconstituted skin (EpiDermTM FT-200) with 
pomegranate-derived products inhibited UVB-induced CPDs and 8-OHdG as well as 
protein oxidation and proliferating cell nuclear antigen (PCNA) protein expression. In 
addition they reported an inhibition of UVB-induced metalloproteinases (collagenase, 
gelatinase, stromelysin, marilysin, elastase and tropoelastin).  
George et al. (2011) examined the chemopreventive efficacy of pomegranate fruit extract 
(PFE) and diallyl sulfide (DAS), alone and in combination, using 2-stage mouse skin 
tumorigenesis model. PFE alone delayed onset and tumor incidence by 55%, while in 
PFE+DAS combination at low doses synergistically decreased tumor incidence more 
potentially (84%). In addition, regression in tumor volume was seen with continuous 
combinatorial treatment (p < 0.01). Mechanistic studies revealed that this inhibition was 
associated with decreased expression of phosphorylated ERK1/2, JNK1 and activated NF-
κB/p65, IKKǂ, IκBǂ phosphorylation and degradation in skin tissue/tumor. Histological 
and cell death analysis also confirmed that combined PFE and DAS inhibit cellular 
proliferation and markedly induce apoptosis than the single agents.  
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4.2.2 Prevention of prostate cancer  
Prostate cancer is the second-leading cause of cancer-related deaths in men in the World. In 
vitro studies stated several pomegranate products inhibit prostate cancer cell growth, induce 
apoptosis of several prostate cancer cell lines, suppress invasive potential of PC-3 cells, and 
decrease proliferation of DU-145 prostate cancer cells (Lansky et al., 2005a,b; Pantuck et al., 
2006). Albrecht et al. (2004) showed that pomegranate seed oil (PSO) as well as polyphenols 
present in the pericarp and fermented juice suppress proliferation and invasion of several 
human prostate cancer cells, LNCaP, PC-3 and DU-145 across the matrigel matrix. Supra-
additive, complementary and synergistic effects were proven in all models. Lansky et al 
(2005b) found equally combined amounts of pomegranate fermented juice, pomegranate 
pulp juice, cold-pressed pomegranate seed oil extracts resulted in a 99% suppression of DU-
145 prostate cancer cell invasion across a matrigel matrix. Ellagic acid, caffeic acid, luteolin 
and punicic acid, important components of pomegranate significantly inhibited in vitro 
invasion of human PC-3 prostate cancer cells when employed individually.  
Malik et al. (2005) showed that pomegranate fruit extract exhibited significant anti-
proliferative and pro-apoptotic activity against highly aggressive human PC-3 cells. The cell 
growth inhibition was dose-dependent, and alterations were in the regulatory molecules 
responsible in the G1 phase of the cell cycle. Another molecular mechanism through which 
pomegranate fruit extract is capable of inducing apoptosis in prostate cancer cells may be 
up-regulation of Bax and down-modulation of Bcl-2. PFE intake was observed to 
significantly slow the progression of tumor growth in athymic nude mice implanted with 
androgen-responsive CWR22R-1 cells. Importantly, this tumor growth inhibition followed a 
significant decrease in the serum levels of PSA. 
Pantuck et al. (2006) studied the effects of pomegranate juice consumption on prostate-
specific antigen (PSA) progression in men with a rising PSA following primary therapy. A 
phase II, Simon two-stage clinical trial for eligible men patients with rising PSA after 
surgery or radiotherapy was conducted. The eligible patients had previous surgery or 
radiation therapy for prostate cancer, Gleason score ≤7, rising PSA value of 0.2-5.0 ng/mL, 
no prior hormonal therapy, and no evidence of metastases. Patients were treated with 8 
ounces of pomegranate juice daily until disease progression. Mean PSA doubling time 
significantly increased with treatment from a mean of 15 months at baseline to 54 months 
posttreatment. In vitro assays comparing pretreatment and posttreatment patient serum on 
the growth of LNCaP showed a 12% decrease in cell proliferation and a 17% increase in 
apoptosis, a 23% increase in serum nitric oxide, and significant reductions in oxidative state 
and sensitivity to oxidation of serum lipids, after versus before pomegranate juice 
consumption.  
Prostate cancer is dependent on circulating testosterone in its early stages and is treatable 
with surgery, radiation therapy, stereotactic radiosurgery, and proton therapy. Both 
androgen and androgen receptor (AR) are recognized risk factors in the development of 
prostate cancer (Heinlein & Chang, 2004). Reduction of circulating levels of androgens and 
suppression of AR are crucial for the treatment of prostate cancer as an elevated level of 
androgen causes enhancement of prostate cancer (Attard et al., 2006). Pomegranate extracts 
has been shown to inhibit both androgen-dependent and androgen-independent prostate 
cancer cell growth. Since androgen and AR play central roles throughout prostate cancer 
development Hong et al. (2008) examined the effects of pomegranate polyphenols, 
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ellagitannin-rich extract and whole juice extract on the expression of genes for key 
androgen-synthesizing enzymes [HSD3B2 (3ǃ-hydroxysteroid dehydrogenase type 2), 
AKR1C3 (aldo-keto reductase family 1 member C3) and SRD5A1 (steroid 5ǂ reductase type 
1)] and AR in LNCaP, LNCaP–AR and DU-145 human prostate cancer cells. Pomegranate 
polyphenols inhibited gene expression and AR most consistently in the LNCaP–AR cell line. 
Therefore, inhibition by pomegranate polyphenols of gene expression involved in androgen-
synthesizing enzymes and the AR may be of particular importance in androgen-
independent prostate cancer cells and the subset of human prostate cancers where AR is up-
regulated. 
Since the anticarcinogenic activity of ellagic acid, the main polyphenol in the pomegranate, 
has been shown on several cancer types Malik et al. (2011) evaluated the effect of ellagic acid 
treatment on the cell viability of human prostate cancer cells. They observed that ellagic acid 
(10-100 mol/L) treatment (48 h) of human prostate carcinoma PC3 cells resulted in a dose 
dependent inhibition of cell growth/cell viability. Ellagic acid caused cell growth inhibition 
which was accompanied by induction of apoptosis, as assessed by the cleavage of poly 
(ADP-ribose) polymerase (PARP) and morphological changes. Further, ellagic acid 
treatment was also found to result in significant activation of caspases, as shown by the dose 
dependent decrease in the protein expression of procaspase-3, -6, -8 and -9. This ellagic acid-
mediated induction of apoptosis was significantly (80-90%) inhibited by the caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-FMK).  
In a study, Koyama et al. (2010) investigated the relationship between pomegranate-induced 
apoptosis in human prostate cancer cells and the insuline-like growth factor (IGF)/IGF 
binding protein (IGFBP) system, as the IGF axis is critical for the regulation of apoptosis in 
many human cancer cell lines and IGFBPs in serum are responsible for regulation of IGF 
action, inhibition of cell proliferation and enhancement of apoptosis in many cell types, 
including prostate (Rajah et al., 1997) and breast (Gucev et al., 1996; Kim et al., 2004) cancers. 
They concluded that there are novel interactions between the IGF system and pomegranate-
induced apoptosis, and pomegranate products modulate the tumor production and 
responsiveness to IGFs and the IGFBPs. Treatment of LAPC-4 prostate cancer cells with 10 
g/mL pomegranate extract, standardized to ellagitannin content (37% punicalagins by 
HPLC), resulted in inhibition of cell proliferation and induction of apoptosis. Co-treatment 
with pomegranate extract and IGFBP-3 revealed synergistic stimulation of apoptosis and 
additional inhibition of cell growth. The researchers also investigated the relationship 
between IGF-1 and pomegranate-induced apoptosis in 22RV-1 prostate cancer cells. Co-
treatment with 100 ng/mL IGF-1 completely blocked apoptosis induction by pomegranate 
extract. In contrast, IGF-I failed to inhibit pomegranate-induced apoptosis in R- cells, 
suggesting the importance of IGF-IR. POMx-treatment decreased Igf1 mRNA expression in 
a dose-dependent manner indicating that its actions also involve tumor-specific suppression 
of IGF-1.  
4.2.3 Prevention of breast cancer  
Along with enthusiastic efforts in early diagnosis, aggressive surgical treatment and 
application of additional non-operative modalities, the prognosis of breast cancer is stil 
chaotic. Pomegranate has been the target of several work in laboratories and cancer centres 
and known to have inhibition properties against diverse types of cancers. Recent review 
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articles reported the laboratory and clinical evidence of cancer chemoprevention or 
treatment of pomegranate fruit, pomegranate juice, pomegranate seed and seed oil on 
prostate, breast, skin, colon, lung, oral and leukaemia cancers, through antioxidant, 
antiproliferation, antiangiogenesis and antiinflammatory mechanisms of action (Adhami et 
al., 2009,2010; Amin et al., 2009; Faria & Calhau, 2011; Johanningsmeier & Harris, 2011). 
They all reported that extracts of pomegranate or the juice are generally more active than 
individual or purified compounds. 
The antiangiogenic potential of pomegranate was evaluated by Toi et al. (2003) where 
VEGF, interleukin-4 and migration inhibitory factor (MIF) were measured in the 
conditioned media of estrogen sensitive MCF-7, estrogen resistant MDA-MB-231 human 
breast cancer cells and MCF-10A immortalized human breast epithelial cells, grown in the 
presence or absence of pomegranate seed oil or fermented juice polyphenols. Polyphenols 
from fermented pomegranate juice, pericarp and oil were shown to inhibit endogenous 
active estrogen biosynthesis with subsequent inhibition of aromatase activity. VEGF was 
strongly downregulated in MCF-10A and MCF-7 cells, and MIF upregulated in MDAMB-
231 cells, representing a marked potential for downregulation of angiogenesis by 
pomegranate fractions. Mehta & Lansky (2004) examined the effects of pomegranate 
fermented juice, cold pressed pomegranate seed oil extract and an HPLC-isoIated peak 
(from the fruit extract-peak B), using the mouse mammary organ culture, an animal model 
of breast cancer having >75% accuracy to predict in vivo carcinogenesis. They showed that 
the purified chromatographic peak of pomegranate fermented juice polyphenols and 
pomegranate seed oil possesses greater chemopreventive potential than that previously 
reported by Kim et al. (2002). While fermented juice polyphenols effected a 42% reduction in 
the number of DMBA-induced cancerous lesions compared with control, purified 
compound, peak B, and pomegranate seed oil each effected an 87% reduction. Peak B is 
believed to be a phenolic compound with potent chemopreventative properties. 
Combination treatment of MCF-7 breast cancer cells with both pomegranate extracts and 
genistein was found to be more effective on inhibition and cytotoxicity than with single 
treatments (Jeune et al., 2005). 
In an ethnobotanical study of medicinal plants in Chandauli District, Singh & Singh (2009) 
were able to document 40 medicinal plants belonging to 27 families by semi-structured 
interviews, field observations, preference and direct matrix ranking with traditional 
medicine practitioners. Pomegranate was found to be an ingredient of a powder for external 
treatment of breast cancer along with whole plant of Vernonia cinerea Less. (AS38) and leaves 
of Crataeva nurvala.  
Epidemiological studies have demonstrated that elevated serum levels of the estrogens, 
mainly estrone and estradiol, and lower levels of sex hormone binding globulin, after 
menopause substantially increased the risk of breast cancer. After menopause, most 
circulating estrogen is derived from the conversion of adrenal androgens to estrone, and 
some of the estrone is further converted to estradiol, the most active estrogen in breast 
tissue. Sturgeon & Ronnenberg (2010) described the in vitro cell culture studies, animal 
studies and available data about the property of pomegranate to prevent breast cancer as 
well as the possible mechanisms involved. They reported that cyclooxigenase inhibition by 
the constituents of the pomegranate fruit, seed oils or pure compounds induce the decrease 
of PGE2 that known to downregulate aromatase expression, that converts adrenal 
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androgens to estrone. Ellagic acid seems to exhibit apoptosis, inhibits activation of 
inflammatory pathways, and inhibits angiogenesis. However, these assays being performed 
in animal models need to be confirmed in humans. 
Grossmann et al. (2010) found that punicic acid inhibited the proliferation of estrogen 
insensitive breast cancer cell line (MDA-MB-231) and an estrogen sensitive cell line 
developed from the MDA-MB-231 cells (MDA-ER 7), as well as induced apoptosis in both 
type of cells 86% and 91% respectively. They stated that punicic acid also disrupted 
mitochondrial membrane potential of both cell lines. Such antiproliferative effect of punicic 
acid on human breast cancer cells was due to lipid peroxidation of cells and activation of 
protein kinase C (PKC).  
Tran et al. (2010) evaluated pomegranate seed linolenic acid isomers as selective estrogen 
receptor modulators (SERMs) in vitro. Punicic acid and -eleostearic acid present in seed oil 
of pomegranate inhibited the IC50 estrogen receptors ER and ERǃ depending on the dose. 
At lower doses of punicic acid acted as agonist for both receptors and antagonist at higher 
concentrations. Both acids were effective in producing effective inhibition of cancer cell 
proliferation: MCF-7 (ER-positive human breast cancer cells) and MDA-MB-231 (ER-
negative human breast cancer cells and are SERMs.  
4.2.4 Prevention of colon cancer  
Current treatment options in colorectal cancer such as surgical intervention and adjuvant 
chemotherapy have several limitations in counteracting the disease. Furthermore, at 
advanced stages the patients might be unresponsive to any form of treatment. In this regard, 
an optimal model for primary and secondary prevention in colon cancer, given the 
availability of effective screening procedures and a well-defined multi-step carcinogenic 
pathway, can be thought as the development of new cancer chemopreventive agents that 
could be employed to inhibit tumor development without causing systemic toxicity such as 
increasing the consumption of food containing anticarcinogenic compounds. 
Phytochemicals from pomegranate have been shown to inhibit colon cancer cell 
proliferation and apoptosis through the modulation of cellular transcription factors and 
signaling proteins (Mertens-Talcott & Percival, 2005; Seeram et al., 2006; Khan, 2009; 
Kasimsetty et al., 2010).  
Kohno et al. (2004a,b) reported that dietary administration of pomegranate seed oil rich in 
conjugated linolenic acid markedly inhibited the development of azoxymethane-induced 
colonic adenocarcinomas in male F344 rats without causing any adverse effects. This was 
associated with an increased content of conjugated linoleic acid in the colon and liver 
and/or increased expression of peroxisome proliferator-activated receptor (PPAR)-protein 
in the non-tumor colon mucosa.  
There is considerable evidence that the anticarcinogenic effect of pomegranate ellagitannins 
is mainly due to ellagic acid, which induces apoptosis in human colon cancer cell line via the 
intrinsic pathway with release of cytochrome c into the cytosol, activation of initiator 
caspase 9 and effector caspase 3 and down-regulation of B-cell lymphoma-extra large (Bcl-
XL). In addition, pomegranate treated Caco-2 cells showed arrest in the S phase of the cell 
cycle, down-regulation of cyclins A and B1 and upregulation of cyclin E (Larossa et al., 
2006).  
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Adams et al. (2006) examined the effects of pomegranate juice on inflammatory cell 
signaling proteins in the HT-29 human colon cancer cell line. In HT-29 colon cancer cells, at 
a concentration of 50 mg/L pomegranate juice significantly suppressed TNFalpha-induced 
COX-2 protein expression by 79%, total pomegranate tannin extract (TPT, 55%), and 
punicalagin 48% Cyclooxygenase-2 (COX-2) expression is increased via activation of nuclear 
factor kappa-B (NFKB) by tumor necrosis factor-alpha (TNF-Ot), an inflammatory cell 
signaling process that may be a cause of cancer initiation and progression. Additionally, 
pomegranate juice reduced phosphorylation of the p65 subunit and binding to the 
NFkappaB response element 6.4-fold. TPT suppressed NFK binding 10-fold, whereas 
punicalagin 3.6-fold. It was shown that inflammatory enzymes in colon cancer cells were 
inhibited by the pomegranate juice components. Ellagic acid, punicalagin and TPT failed to 
induce apoptosis in HT-29 and HCT-116 cells when treated at doses equivalent to found in 
pomegranate juice. They were only effective when treated at equivalent doses of 100μg/mL 
(Seeram et al., 2005).  
In a seperate study, Boateng et al. (2007) examined the effect of pomegranate juice given 
access to 20%, before and after treatment with colon-specific chemical carcinogen, 
azoxymethanein to F-344 rats for 17 weeks. Pomegranate fruit juice reduced the number of 
aberrant cryptic foci (ACF) of the colon by 91% in male rats. Histopathology of rat colon 
after 17th week of treatment revealed a remarkable decrease in the number of large crypts in 
pomegranate juice-fed rats, and the number of crypts/ACF was also low. When compared 
to water melon and cranberry juices, pomegranate juice was found to be superior as an 
inhibitor of ACF in rat colon. Increase in weight gain and feed intake was observed in 
pomegranate fruit juice-fed rats, suggesting a possible protective effect against cancer 
cachexia. 
Kasimsetty et al. (2010) investigated the colon cancer chemopreventive properties of 
pomegranate ellagitannins and their intestinal bacterial metabolites, urolithins, in HT-29 
human colon cancer cells, and stated that the ellagitannins and urolithins released in the 
colon upon consumption of pomegranate juice in considerable amounts could potentially 
reduce the risk of colon cancer development, by inhibiting cell proliferation and inducing 
apoptosis. Ellagitannins and urolithins inhibited endocrine disrupter 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1-mediated ethoxyresorufin-O-deethlyase 
(EROD) activity in vitro with IC50 values ranging from 56.7 M for urolithin A to 74.8 M for 
urolithin C. These compounds exhibited dose- and time-dependent decreases in cell 
proliferation and clonogenic efficiency of HT-29 cells.  
In colon cancer, a large percentage of the tumour arises from activating mutations in the 
Wnt protein pathway. Sharma et al. (2010) studied the effects of urolitinins, ellagic acid and 
ellagitannin-rich fruit extracts on Wnt signalling in a human 293T cell line using a luciferase 
reporter of canonical Wnt pathway-mediated transcriptional activation. In the canonical 
Wnt pathway, the signal produced by the binding of Wnt ligands to cell surface receptors is 
transmitted through a cytoplasmic protein called disheveled (Dvl) to inhibit the activity of a 
complex of cellular proteins that phosphorylate β-catenin, and target it for destruction. 
Therefore, Dvl-mediated inhibition of the β-catenin destruction complex results in increased 
levels of cellular ǃ-catenin and translocation of β-catenin into the nucleus, where β-catenin 
activates transcription factors of the LEF/TCF families and initiates transcription of target 
genes effective on tissue proliferation, differentiation and tumorigenesis. The researchers 
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concluded that urolithins produced in the colon from ellagitannins present in pomegranate 
are inhibitors of the canonical Wnt signalling pathway at physiologically relevant 
concentrations. 
4.2.5 Prevention of other cancer types  
Eventhough there are advances in detection and therapy of cancer, the severe morbidity rate 
from cancer have not improved. Various parts of the pomegranate plant have been stated to 
exert selective antiproliferative effects on a lung, leukemia, stomach, bladder, oesaphagus 
and oral cancers (Lansky & Newman, 2007; Syed et al., 2007; Heber, 2008; Jurenka, 2008; 
Rahman et al., 2010; Khan & Mukhtar, 2010; Faria & Calhau 2011), through antioxidant, 
antiproliferation (growth inhibition, cell cycle disruption and apoptosis), antiangiogenesis 
and antiinflammatory mechanisms of action. 
In vitro and in vivo studies revealed that pomegranate fruit extract (PFE) have 
chemopreventive/therapeutic potential of against lung cancer models (Khan et al., 
2007a,b,2008). Normal human bronchial epithelial cells (NHBE) and human lung carcinoma 
A549 cells, in mice, were treated with pomegranate fruit extract (50–150 µg/ml) for 72 h. 
There was a significant decrease in the viability of A549 cells, however, only minimal effects 
were observed on NHBE cells. Pomegranate fruit extract treatment of A549 cells resulted in 
dose-dependent arrest of cells in G0/G1 phase of the cell cycle, which was associated with 
induction of WAF1/p21 and KIP1/p27 and accompanied by decrease in the expression of 
downstream cell cycle regulatory proteins (Khan et al., 2007a).  
The effect of oral consumption of a human achievable dose of pomegranate fruit extract on 
tumor growth, progression and signaling pathways involved, was studied further in two 
other mouse lung tumor protocols. Benzo(a)pyrene [B(a)P] and N-nitroso-tris-
chloroethylurea (NTCU) were used to induce lung tumors, and PFE was given in drinking 
water to A/J mice. Lung tumor yield was examined on the 84th day and 140 days after B(a)P 
dosing and 240 days after NTCU treatment. Mice treated with PFE and exposed to B(a)P and 
NTCU had statistically significant lower lung tumor multiplicities than mice treated with 
carcinogens only. Tumor reduction was 53.9% and 61.6% in the B(a)P+PFE group at 84 and 
140 days, respectively, compared with the B(a)P group. The NTCU+PFE group had 65.9% 
tumor reduction compared with the NTCU group at 240 days. PFE treatment also resulted 
in inhibition of NF-κB, MAPK, and PI3K/Akt signaling. Treatment with B(a)P and NTCU 
caused increased phosphorylation of mTOR at Ser2448, whereas PFE administration resulted 
in inhibition of phosphorylation of mTOR. This observation was significant since the mTOR 
integrates mitogenic signals and intracellular nutrient levels to activate 4EBP1 and p70S6K 
that control protein translation and cell cycle progression (Khan et al., 2007b).  
Suzuki et al. (2001) investigated cytotoxicity of pomegranate seed oil and other plant seed 
oils containing conjugated linoleic acids in mouse tumors and human monocytic leukemia 
cells. They stated the cytotoxic effect of pomegranate seed oil (containing 9c,11t,13c-18:3), as 
well as tung seed oil (containing 9c,11t,13t-18:3) and catalpa seed oil (containing 9t,11t,13c-
18:3), was much stronger than that of pot marigold seed oil (containing 8t,10t,12c-18:3), 
suggesting that the position of the double bond could be an important determinant for the 
cytotoxicity of conjugated inoleic acids. 
Kawaii & Lansky (2004) examined the effect of flavonoid-rich pomegranate juice, 
pomegranate fermented juice and pomegranate pericarp extracts on HL-60 human leukemia 
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cell differentiation and proliferation. In vitro assays confirmed that both the pomegranate 
fermented juice and pericarp extracts strongly promoted cellular differentiation and 
inhibited proliferation in HL-60 cell cultures; the effect of pomegranate juice on cellular 
differentiation was less significant. In view of the observations the authors stated the 
hypothesis of another mechanism by which pomegranate constituents impart an 
anticarcinogenic effect. 
Mertens-Talcott & Percival (2005) investigated the interactions of ellagic acid and quercetin 
with resveratrol, with the hypothesis that the selected polyphenols would interact 
synergistically in the induction of apoptosis and reduction of cell growth in human 
leukemia cells (MOLT-4). They found significant interaction for the combination of ellagic 
acid with resveratrol, and alterations in cell cycle kinetics induced by single compounds and 
combinations were also observed. The authors concluded that the anticarcinogenic potential 
of foods containing polyphenols may not be based on the effects of individual compounds, 
but may involve a synergistic enhancement of the anticancer effects. 
4.3 Other health effects  
4.3.1 Antiinflammatory activity  
Epidemiological evidence points that many cancers arise from sites of infection, chronic 
irritation and inflammation (Rakoff-Nahoum, 2006; Heber, 2008). The inflammatory 
response result in persistent oxidative stress orchestrates tumour microenvironment to 
microbial infection and mediates tissue repair and regeneration, which may occur due to 
infectious or non-infectious tissue damage. 
Pomegranate and the selected chemical constituents isolated from juice, peel, and seed 
have been found to have a large range of effects: (i) inhibition of Cyclooxygenase-2 (COX-
2) expression and ultimately eicosanoid biosynthesis (Schubert et al., 1999; Shukla et al., 
2008); (ii) synergistic suppression of inflammatory cytokine expression (Adams et al., 
2006); (iii) inhibition of matrix MMPs (Okamoto et al., 2004; Ahmad et al., 2005; Aslam et 
al., 2006). 
In view of the antioxidant, anticarcinogenic and antiinflammatory properties of 
pomegranate phenolics and/or its derived metabolites, one could hypothesize that 
pomegranate and/or its derived metabolites have a beneficial effect on inflammation. 
Larrosa et al. (2010) evaluated the effects of pomegranate intake and its main microbiota-
derived metabolite urolithin-A (UROA) on colon inflammation in a dextran sodium sulfate 
(DSS)-induced colon inflammation rat model and to assess whether UROA is the main anti-
inflammatory compound. In addition, they examined the effect of the inflammation on the 
phenolic metabolism. DSS (5%) was administered for the five last days to Male Fisher rats, 
fed with 250 mg/kg day pomegranate extract or 15 mg/kg day UROA for 25 days. In both 
groups inflammation markers (iNOS, COX-2, PTGES and PGE2 in colonic mucosa) were 
decreased, the gut microbiota was modulated and the G1 to S cell cycle pathway was up-
regulated. UROA group showed various down-regulated pathways, including that of the 
inflammatory response. Pomegranate extract, but not UROA, decreased oxidative stress in 
plasma and colon mucosa. Only UROA preserved colonic architecture. The normal 
formation of urolithins in pomegranate extract-fed rats was prevented during inflammation 
suggesting UROA could be the most active anti-inflammatory compound derived from 
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pomegranate ingestion in healthy subjects, whereas in colon inflammation, the effects could 
be due to the nonmetabolized ellagitannin-related fraction. 
Structure–activity relationships of natural products have been found to influence the 
various pharmacological functions. In vitro and in vivo antiinflammatory effects of Punica 
granatum Linne, a high phenolic content fruit, widely used as an antipyretic analgesic in 
Chinese culture, were investigated by Lee et al. (2010). Pomegranate has shown potential 
nitric oxide (NO) inhibition in liposaccaharide (LPS)-induced RAW 264.7 macrophage cells, 
with significant decrease in carrageenan-induced mice paw edema. Hydrolysable tannins, 
punicalagin, punicalin, strictinin A, and granatin B, inhibited NO production and inductible 
nitric oxide synthase (iNOS) expression in RAW 264.7 cells. Granatin B showed the strongest 
iNOS and COX-2 inhibitory effects, and exhibited these effects in the inhibition of paw 
swelling and the prostaglandin (PG) E2 level in carrageenan-induced mice.  
Inflammatory disorders are due to excessive production of pro-inflammatory mediators 
such as TNFa, GM-CSF, IL-1, IL-6, IL-8, leukotriene B4 and PAF, the activity of 
inflammatory cells such as neutrophils, monocytes and macrophages, and excessive 
production of reactive oxygen species (ROS) (Nathan, 2006). Bachoual et al. (2011) 
investigated the effect of pomegranate peel aqueous extract (PPAE) on human neutrophil 
reactive oxygen species (ROS) production in vitro and on LPS-induced lung inflammation in 
vivo in mice. PPAE, in a concentration-dependent manner, inhibited luminol-amplified 
chemoluminescence of resting neutrophils and N-formyl-methionylleucyl- phenylalanine 
(fMLF)- or phorbol myristate acetate (PMA)-stimulated neutrophils. On the contrary, had no 
significant effect on superoxide anion generation, suggesting that it does not directly inhibit 
NADPH oxidase activity or activation pathways, or scavenge superoxide anions. In vivo 
studies showed that PPAE also attenuated LPS-induced lung inflammation in mice. 
Consequently PPAE found to inhibit neutrophil myeloperoxidase activity and attenuates 
LPS-induced lung inflammation in mice.  
4.3.2 Cardiovascular health  
Cardiovascular diseases (CVDs) are a leading cause of death and disability worldwide. 
Hypertension and atherosclerosis, a chronic inflammatory disease characterized by plaque 
formation in the large arteries, are major risk factors for CVDs, such as stroke, myocardial 
infarction and heart failure. In addition to genetic factors, age, body weight, blood pressure, 
dyslipidemia, physical inactivity and behavioural risk factors such as tobacco or alcohol use, 
diets that include high fat, salty food are thought to play an important role in the 
development of cardiovascular disease. Epidemiological data have clearly shown that 
independent risk factors for CVD are serum total cholesterol and low-density lipoprotein 
cholesterol (LDL-C) (Kannel et. al., 1986; Mirmiran et al., 2009). A large number of clinical 
trials have demonstrated in order to prevent these cardiovascular diseases from occurring, 
control of a patient’s blood pressure is necessary, either by lifestyle modifications, 
medication(s) such as use of cholesterol-lowering statins, antihypertensive drugs and 
antiplatelet agents or both.  
While modification of dietary patterns and increased physical activity constitute the primary 
preventive intervention in lowering coronary heart disease (CHD) and stroke, the role of 
plant-based bioactive compounds or phytochemicals has attracted much attention since 
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there is a negative relationship between their consumption and CVDs (Hu, 2003; Dauchet et 
al., 2005; Nothlings et al., 2008). Pomegranate, being rich in flavonoids and ellagitannins, are 
potent antioxidants and antiinflammatory agents, thereby counteracting oxidative damage 
and inflammation which underlie the pathogenesis of CVD (Kaplan et al., 2001). Oxidative 
stress, the major contributor to CVD, is the build-up of highly reactive free radical species or 
the decrease of defence mechanisms to protect against biological damage by free radicals 
due to the imbalance between free radical formation and antioxidant status. Oxidative stress 
induces inflammation by acting on the pathways that generate inflammatory mediators like 
adhesion molecules and pro-inflammatory cytokines. The effect of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) on human health has been studied for decades, 
with results indicating increasing the risk of cancer, arthritis, degenerative eye and 
neurological disorders, as well as general aging (Aruoma, 1998). However, the attention has 
turned to the effect of these free radicals on CVD and related disorders; such as 
atherosclerosis, hypertension, hypercholesterolemia, type 2 diabetes, and heart failure 
(Hamilton et al., 2004). 
Sumner et al. (2005) investigated the effect of daily consumption of pomegranate juice for 3 
months on myocardial perfusion in patients who had coronary heart disease and 
myocardial ischemia in a randomized, placebo-controlled, double-blind study. The patients 
were given either 240 mL pomegranate juice (polyphenol content not specified) or a sports 
beverage of similar color, flavor, and caloric content daily for three months. Although both 
control and treatment patients demonstrated similar levels of stress-induced ischemia at 
baseline, at three months stress-induced ischemia decreased in the treatment group (from 
4.5±3.1 to 3.7±3.7). In addition, angina episodes decreased 50% percent in the treatment 
group but increased 38% in the placebo group. The researchers concluded that pomegranate 
juice consumption resulted in a reduction in myocardial ischemia and improvement in 
myocardial perfusion.  
Rosenblat et al. (2006) studied the antiatherosclerotic effects of a pomegranate by-product 
(PBP, which includes the whole pomegranate fruit left after juice preparation). Four-
month-old E° mice with significant atherosclerosis were given PBP (17 or 51.5 μg of gallic 
acid equiv/kg/day) with an eight-fold higher polyphenol concentration than 
pomegranate juice for three months. Consumption of PBP by the mice resulted in a 
significant reduction in atherosclerotic lesion size by up to 57% and in MPM oxidative 
status as evidenced by a 27% decrease in total macrophage peroxide levels, a 42% 
decrease in cellular lipid peroxide levels, and a 19% decrease in peritoneal macrophage 
uptake of oxidized LDL (Ox-LDL).  
Through in vitro and in vivo studies de Nigris et al. (2006) stated that the proatherogenic 
effects induced by perturbed shear stress can be also reversed by chronic administration of 
pomegranate fruit extract (PFE). The researcher investigated the effects of intervention with 
the PFE rich in polyphones (punicalagin, which is a potent antioxidant) on ELK-1, p-CREB, 
and endothelial nitric oxide synthase (eNOS) expression induced by high shear stress. Both 
the PFE and the regular pomegranate juice concentrate reduced the activation of ELK-1 and 
p-CREB and increased eNOS expression in cultured human endothelial cells and in 
atherosclerosis-prone areas of hypercholesterolemic mice. PFE and pomegranate juice 
increased cyclic GMP levels while there was no significant effect of both compounds on the 
conversion of L-arginine to L-citrulline. Administration of these compounds to 
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hypercholesterolemic mice significantly reduced the progression of atherosclerosis and 
isoprostane levels and increased nitrates.  
In a randomized, double-blind, parallel trial Davidson et al. (2009) assessed the influence of 
pomegranate juice consumption on anterior and posterior carotid intima-media thickness 
(CIMT) progression rates in subjects at moderate risk for coronary heart disease. 
Participants consumed 240 ml/day of pomegranate juice or a control beverage for up to 18 
months. No significant difference in overall CIMT progression rate was observed between 
pomegranate juice and control treatments. In exploratory analyses, in subjects in the most 
adverse tertiles for baseline serum lipid peroxides, triglycerides (TGs), highdensity 
lipoprotein (HDL) cholesterol, TGs/HDL cholesterol, total cholesterol/HDL cholesterol, and 
apolipoprotein-B100, those in the pomegranate juice group had significantly less anterior 
wall and/or composite CIMT progression versus control subjects. They concluded that in 
subjects at moderate coronary heart disease risk, pomegranate juice consumption had no 
significant effect on overall CIMT progression rate but may have slowed CIMT progression 
in subjects with increased oxidative stress and disturbances in the TG-rich lipoprotein/HDL 
axis. 
Endothelial apoptosis is a driving force in atherosclerosis development. Oxidized low-
density lipoprotein (oxLDL) promotes inflammatory and thrombotic processes and is highly 
atherogenic, as it stimulates macrophage cholesterol accumulation and foam cell formation. 
In recent years ellagic acid has been the subject of intense research within the fields of cancer 
and inflammation, however, its protective effect against oxidized LDL-induced injury in 
vascular endothelial cells have not been clarified. Ou et al. (2010) investigated the anti-
apoptotic effect of ellagic acid in human umbilical vein endothelial cells (HUVECs) exposed 
to OxLDL and explored the possible mechanisms. Pretreatment with ellagic acid (5–20 μM) 
significantly attenuated OxLDL-induced cytotoxicity, apoptotic features, and generation of 
ROS. In addition, the antiapoptotic effect of ellagic acid was partially inhibited by 
wortmannin (a PI3K inhibitor) and cavtratin (a specific endothelial NO synthase inhibitor). 
The alterations induced by OxLDL, however, were attenuated by pretreatment with ellagic 
acid. The inhibition of OxLDL-induced endothelial apoptosis by ellagic acid is due to its 
anti-oxidant activity and its ability to modulate the PI3K/Akt/eNOS signaling pathway 
upto a point. 
4.3.3 Antidiabetic properties (glucose and lipid metabolism activity)  
According to several review articles (Jurenka, 2008; Li et al., 2008; Yun, 2010) pomegranate 
flowers, containing abundant ellagitannins, was already prescribed in Unani and Ayurvedic 
systems of medicine as a remedy for diabetes. The protective effect of pomegranate flowers’ 
extracts (PFLE) was investigated by some authors on blood glucose level, serum lipid 
profile, total cholesterol, LDL, pancreatic lipid peroxidation and activities of both enzymatic 
and non-enzymatic antioxidant status in diabetic rats (Huang et al., 2005a,b; Lei et al., 2007; 
Lan et al., 2009; Bagri et al., 2009). The authors reported that the increase in blood glucose 
level, total cholesterol, triglycerides, LDL-cholesterol, very low density lipoproteins, lipid 
peroxidation level with decrease in high density lipoprotein (HDL)-cholesterol, glutathione 
content and antioxidant enzymes namely, glutathione peroxidase, glutathione reductase, 
glutathione-S-transferase, superoxide dismutase and catalase can be reversed by 
administration of aqueous PFLE. PFLE was shown to activate PPAR-a, a cardiac 
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transcription factor involved in myocardial energy production via fatty acid uptake and 
oxidation. PPAR-a activation decreased cardiac uptake and circulation of Iipids. Decreases 
were observed in cardiac tissue triglycéride content at the end of the study and in plasma 
total cholesterol and NEFA after four weeks of treatment.These findinds suggest that 
pomegranate could be used as dietary supplement in the treatment and prevention of 
chronic diseases characterised by atherogenic lipoprotein profile, aggravated antioxidant 
status and impaired glucose metabolism.  
Rosenblat et al. (2006) investigated the effect of 50 mL/day pomegranate juice for three 
months on oxidative stress, blood sugar, and lipid profiles in 10 type 2 diabetic patients, 
with a history of diabetes for 4–10 years, and 10 healthy controls. In diabetic patients, 
triglyceride levels were 2.8 times greater, (HDL) cholesterol was 28% lower, and hemoglobin 
AlC (HbAlC) values were 59% higher than in control patients. They stated that consuming 
pomegranate juice for three months did not significantly affect triglyceride, HDL 
cholesterol, HbAlC, glucose, or insulin values, but did lower serum C-peptide values by 
23%, suggesting improved insulin sensitivity. Researchers concluded that despite the sugars 
naturally present in pomegranate juice, consumption did not adversely affect diabetic 
parameters but had a significant effect on atherogenesis via reduced oxidative stress.  
Esmailzadeh et al. (2006) investigated the cholesterol-lowering effects of 40 g concentrated 
pomegranate juice on 22 type 2 diabetic patients (8 men and 14 women) for eight weeks. 
Statistically significant decreases were observed in total cholesterol, LDL cholesterol, 
total/HDL cholesterol ratio, and LDL/HDL ratio, which due in part to decreased absorption 
and increased fecal excretion of cholesterol, as well as possible affects on HMG-CoA 
reductase and sterol O-acyltransferase, two enzymes key to cholesterol metabolism.  
Oleanolic acid, ursolic acid and gallic acid, active components contained in pomegranate 
flower (Li et al., 2008), have long been recognized to have antihyperlipidemic properties 
(Liu, 1995; Jang et al., 2008). Xu et al. (2009) speculated that PFLE might improve diabetes 
and obesity-induced fatty liver, and investigated the effects and underlying mechanisms of 
action of PFLE on hepatic lipid accumulation in ZDF rats with severe fatty liver and in 
human liver-derived HepG2 cell line. PFLE-treated ZDF rats showed reduced ratio of liver 
weight to tibia length, hepatic triglyceride contents and lipid droplets. These effects were 
accompanied by enhanced hepatic gene expression of peroxisome proliferator-activated 
receptor (PPAR)-alpha, carnitine palmitoyltransferase-1 and acyl-CoA oxidase (ACO), and 
reduced stearoyl-CoA desaturase-1. Incontrast, PFLE showed minimal effects on expression 
of genes responsible for synthesis, hydrolysis or uptake of fatty acid and triglycerides. PGF 
treatment also increased PPAR-alpha and ACO mRNA levels in HepG2 cells. The authors 
concluded that PFLE, an Unani medicine, ameliorates diabetes and obesity-associated fatty 
liver, at least in part, by activating hepatic expression of genes responsible for fatty acid 
oxidation. 
There is growing evidence that paraoxnase (PON1) plays an important role in lipid 
metabolism, particularly in protecting LDL and HDL from oxidation in vitro, and thus 
lowering the risk of developing atherosclerosis, and the onset of cardiovascular disease 
(Mackness et al., 2000,2002). PON1 knockout mice exhibit about a two-fold increase in 
atherosclerosis (Rozenberg et al., 2003), whereas PON1 expression and activity can be 
modulated by dietary polyphenols i.e. LDL receptor deficient mice supplemented with 
quercitine (a polyphenol contained in pomegranate) and moderate ethanol inhibited the 
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progression of atherosclerosis by upregulating the hepatic expression with concomitant 
increased serum PON1 activity (Gouédard et al., 2004; Leckey et al., 2010). Similarly, 
pomegranate polyphenols seem to have a specific transcriptional role in hepatocyte PON1 
expression upregulation (Khateeb et al., 2010). Although it is known that diabetes is 
associated with increased oxidative stress and the development of atherosclerosis 
(Mooradian, 2009), no expression studies have been examined in a diabetic model that is fed 
with high fat. Therefore, Betanzos-Cabrera et al. (2011) investigated whether pomengranate 
juice induces PON1 gene expression and activity, especially in conditions known for 
affecting PON1 enzymatic function. The feeding of streptozotocin-induced diabetic mice 
with a high-fat diet supplemented daily with pomegranate juice significantly induced PON1 
gene expression and activity. Interestingly, animals supplemented with pomegranate juice 
showed the lowest bodyweight. In addition, the pomegranate juice significantly reduced 
blood glucose but not triacylglycerols and cholesterol levels, demonstrating that 
pomegranate juice has a hypoglycemic effect.  
4.3.4 Antimicrobial properties  
Due to the increasing interest in natural antimicrobials and antioxidants derived from plant 
sources the investigation of pomegranate has also been an interesting scientific field for 
researchers, since the capacity of preventing infections of pomegranate extracts was well 
documented. Food-borne illnesses are still an important concern for both consumers, the 
food industry and food safety authorities, thus, the ongoing search for natural 
antimicrobials for prevention of food-borne illnesses is a vast exploring area for scientists. 
Antimicrobial activities of pomegranate have been studied by some researchers and the 
extent of inhibitory effect is always attributed to the pomegranate antioxidant activity that 
depends mainly on the phenolic and anthocyanin content of the fruit (Holetz et al., 2002; 
Braga et al., 2005; Mathabe et al., 2006; McCarrell et al., 2008; Al-Zoreky, 2009; Duman et al., 
2009; Gould et al., 2009; Parashar et al., 2009; Panichayupakaranant et al., 2010, Orak et al., 
2011). In a previous study, Opara et al. (2009) reported that the best activity against 
Staphyloccocus aureus and Pseudomonas aeruginosa were found in fruit peel compound 
punicalagin, particularly from Oman, which was coincident with the highest levels of 
vitamin C detected in these samples. Similar findings were reported by Salgado et al. (2009) 
and Dahham et al. (2010) in which antibacterial and antifungal activities of pomegranate 
peel extract (rind), seed extract, juice and whole fruit on the selected bacteria and fungi were 
investigated. The antimicrobial effectiveness of the extracts depends on the species of 
bacteria evaluated, the more sensitive being the Gram-positive species S. aureus and Bacillus 
sp. along with Aspergillus niger. Voravuthikunchai et al. (2006) tested pomegranate and seven 
other Thai medicinal plant extracts for in vitro activity against enterohemorrhagic Escherichia 
coli (E. coli O157:H7). An ethanolic pomegranate peel extract was shown to be both 
bacteriostatic and bacteriocidal, indicating it may be an effective adjunct treatment for E. coli 
O157:H7 infection. 
The only human trials examining the antibacterial properties of pomegranate extracts have 
focused on oral bacteria (Sastravaha et al., 2003; Menezes et al., 2006). However, several in 
vitro assays demonstrate its bacteriocidal activity against several highly pathogenic and 
sometimes antibiotic-resistant organisms. Machado et al. (2002) evaluated the synergistic 
effect of a pomegranate methanolic extract with five antibiotics on 30 clinical isolates of 
methicilin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus. Antibiotics tested 
were. Although synergistic activity between the pomegranate extract and tested antibiotics 
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(chloramphenicol, gentamicin, ampicillin, tetracycline, and oxacillin) was noted in the S. 
aureus isolates, synergy with ampicillin was the most pronounced. A combination of the two 
increased the lag time to bacterial growth by three hours and was also bacteriocidal as 
evidenced by a 72.5% reduction in methicillin-sensitive organisms and a 99.9% reduction in 
MRSA. Bialonska et al. (2009b) stated that commercial extract of pomegranate by-product 
provided by POM Wonderful (Los Angeles, CA) and punicalagins inhibited the growth of 
pathogenic clostridia and S. aureus. Nevertheless the probiotic lactobacilli and bifidobacteria 
were not affected by ellagitannins. These findings lead to the conclusion that the growth 
inhibition toward pathogenic bacteria could be attributed to the accumulation of 
ellagitannins in the large intestines, where they interact with complex gut microflora, and 
lower media pH due to the presence of punicalagins. 
Su et al. (2010) stated that the combination of pomegranate juice and pomegranate 
polyphenols was also effective against food-borne viral infectivity and appear to be 
promising natural remedies for preventing or reducing human norovirus infections. In 
addition, pomegranate purified polyphenol extract inhibited influenza virus having also a 
synergistic effect with oseltamivir, since influenza continues to be a major cause of mortality 
and morbidity eventhough the applications of the vaccines and antiviral therapies (Haidari 
et al., 2009).  
Johann et al. (2010) studying the activity of extracts of some plants used in Brazilian 
traditional medicine against the pathogenic fungus that causes this Paracoccidioidomycosis, 
Paracoccidioides brasiliensis, reported that the hexane extract of pomegranate stem exhibited 
better antifungal activity against the three clinical isolated than other parts of the plant or 
other fractions of the same plant.  
Candida species, a normal component of the human biota in the gastrointestinal tract and 
oral and vaginal mucosa, can cause superficial infections such as thrush and vaginitis. Endo 
et al. (2010) reported that punicalagin isolated from pomegranate peels possessed strong 
activity against Candida albicans and C. parapsilosis as well as the combination of punicalagin 
and fluconazole showed a synergistic interaction. Tayel & El-Tras (2009) demonstrated that 
methanol, ethanol and water extracts of pomegranate peels were effective against C. albicans 
growth. In addition, they also proved that pomegranate peel extract aerosol was an efficient 
method for complete sanitizing of semi-closed places against C. albicans growth, and thereby 
could contribute for preventing C. albicans contamination and growth in suspected places. 
Ethnobotanical studies performed in Brazil had demonstrated the utilization of 
pomegranate in oral health since denture stomatitis is commonly associated with C. albicans 
and some other Candida species (Santos et al., 2009). 
Dell’Agli et al. (2009) studied the in vitro antiplasmodial and antimalarial activity of 
methanolic extracts of a tannin-enriched fraction and of metabolites to estimate their 
curative efficacy and mechanisms of action. They conclude that methanolic extracts of 
pomegranate inhibited Plasmodium falciparum and P. vivax growth in vitro, and suggested 
that these might be attributed to the low bioavailability as well as the kinetic of conversion 
of ellagic acid to inactive metabolites urolithins. 
5. Adverse effects and reactions/safety 
Pomegranate and its products have a long history of use as food or ethnic medicine 
without adverse effects, and also it has GRAS (generally recognized as safe) status in the 
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USA. The published safety data is limited and no clinical or laboratory adverse events 
were reported. However, there are some publications on occurrence of allergic reactions 
when handling or ingestion of pomegranate fruit/seeds due to eliciting a type I 
hypersensitivity reaction, and thus it is crucial to advise consumers the side effects 
(McCutcheon et al., 2008).  
6. Conclusion  
Nowadays, it is widely accepted that the beneficial health effects of fruits and vegetables in 
the prevention of diseases are due to the bioactive compounds they contain.  
Based on the explosion of interest in the numerous therapeutic properties over the last 
decade and in vitro, animal, and clinical trials pomegranate seems to be a promising food 
with well-defined therapeutic benefits. The epidomiological data suggests that the 
pomegranate fruit and its associated bioactive compounds such as phenolic acids, 
flavonoids, and tannins may possess a strong potential as a chemopreventive and possibly 
as new tools for preventive and possibly therapeutic interventions against various human 
cancers. This could have a direct practical implication to cancer patients if consumption of 
fruits like pomegranate can inhibit the process of carcinogenesis. Further studies should 
focus on the potential clinical usefulness of the agent through issues such as determining the 
optimal period and route of administration, systemic bioavailability, potent anticancer 
activity, optimal dosing and toxicity (if any) of the agent and single or combinatorial 
approach. In addition, the possible use of pomegranate extracts as a therapy or adjunct for 
prevention and treatment of several disease processes, such as diabetes, cardiovascular 
disease, atherosclerosis, inflammation, microbial infection, obesity, male infertility, 
Alzheimer underscores the need for more clinical research. Therefore, ongoing studies 
should focus on developing novel pomegranate derived products such as ready-to-eat 
pomegranate seeds, single-strength juices, juice concentrates, seeds in syrup, frozen seeds, 
and traditional products such as pomegranate pekmez, leather and molasses, to benefit from 
these constituents throughout a healthy life cycle. 
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